Mechanical behavior of in vivo degraded second generation resorbable magnesium scaffolds (RMS)

被引:13
作者
Brandt-Wunderlich, Christoph [1 ]
Ruppelt, Philipp [2 ]
Zumstein, Philine [2 ]
Schmidt, Wolfram [3 ]
Arbeiter, Daniela [3 ]
Schmitz, Klaus-Peter [1 ,3 ]
Grabow, Niels [3 ]
机构
[1] Inst ImplantTechnol & Biomat eV, Friedrich Barnewitz Str 4, D-18119 Rostock, Germany
[2] BIOTRONIK AG, Bulach, Switzerland
[3] Rostock Univ, Med Ctr, Inst Biomed Engn, Rostock, Germany
关键词
Resorbable scaffold; Magnesium; in vivo degradation; Mechanical properties; Vascular restoration; Magmaris; ABSORBABLE METAL SCAFFOLD; BIORESORBABLE SCAFFOLDS; BIOSOLVE-II; SUSTAINED SAFETY; PERFORMANCE; VITRO; CORROSION; MULTICENTER; PARADIGM; ALLOYS;
D O I
10.1016/j.jmbbm.2018.12.008
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Resorbable magnesium scaffolds are used for the treatment of atherosclerotic coronary vascular disease and furthermore, for vascular restoration therapy. Recently, the first-in-man clinical studies with Magmaris showed promising results regarding the target lesion failure as well as vasomotion properties after 12 and 24 month. The consistency of in vivo degraded magnesium alloys in a cardiovascular environment is qualitatively described in literature, but only little has been disclosed about the actual change in mechanical properties and the behavior of the magnesium alloy degradation products. In the present study, uncoated magnesium scaffolds 3.0 x 20 mm were implanted in coronary arteries of two healthy Goetinriger mini-swine. The scaffolds were explanted to evaluate the mechanical properties of the degraded magnesium scaffolds after 180 days in vivo. Ex vivo sample preparation and test conditions were adapted to a customized compression test setup which was developed to investigate the micro-scale scaffold fragments (width 225 +/- 75 mu m, thickness 150 mu m). As reference bare undegraded magnesium scaffold fragments were tested. Mechanical parameters relating to force as a function of displacement were determined for both sample groups. The undegraded samples showed no fracturing at the maximum applied force of 8 N, whereas the in vivo degraded test samples showed forces of 0.411 +/- 0.197 N at the first fracturing and a maximum force of 0.956 +/- 0.525 N. The deformation work, calculated as area beneath the force-displacement curve, of the in vivo degraded test samples was reduced by approximately 87-88% compared to the undegraded samples (5.20 mN mm and 40.79 mN mm, both at 7.5% deformation). The indication for a complete loss of structural integrity through a reduction of mechanical properties after a certain degradation time increases the chance to restore vascular function and physiological vasomotion in the stented vessel compartment.
引用
收藏
页码:174 / 181
页数:8
相关论文
共 25 条
[1]   A new in vitro-in vivo correlation for bioabsorbable magnesium stents from mechanical behavior [J].
Bowen, Patrick K. ;
Drelich, Jaroslaw ;
Goldman, Jeremy .
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2013, 33 (08) :5064-5070
[2]   In vitro and in vivo corrosion measurements of Mg-6Zn alloys in the bile [J].
Chen, Yigang ;
Yan, Jun ;
Wang, Zhigang ;
Yu, Song ;
Wang, Xiaohu ;
Yuan, Ziming ;
Zhang, Xiaonong ;
Zhao, Changli ;
Zheng, Qi .
MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS, 2014, 42 :116-123
[3]  
Farè Stefano, 2010, Matéria (Rio J.), V15, P96, DOI 10.1590/S1517-70762010000200002
[4]   Plastic strains during stent deployment have a critical influence on the rate of corrosion in absorbable magnesium stents [J].
Galvin, Emmet ;
Cummins, Christy ;
Yoshihara, Shoichiro ;
Mac Donald, Bryan J. ;
Lally, Caitriona .
MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING, 2017, 55 (08) :1261-1275
[5]  
Haude M, 2017, EUROINTERVENTION, V13, P432, DOI [10.4244/EIJ.D.17.00254, 10.4244/EIJ-D-17-00254]
[6]   Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial [J].
Haude, Michael ;
Ince, Huseyin ;
Abizaid, Alexandre ;
Toelg, Ralph ;
Lemos, Pedro Alves ;
von Birgelen, Clemens ;
Christiansen, Evald Hoj ;
Wijns, William ;
Neumann, Franz-Josef ;
Kaiser, Christoph ;
Eeckhout, Eric ;
Lim, Soo Teik ;
Escaned, Javier ;
Onuma, Yoshinobu ;
Garcia-Garcia, Hector M. ;
Waksman, Ron .
EUROPEAN HEART JOURNAL, 2016, 37 (35) :2701-2709
[7]   Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial [J].
Haude, Michael ;
Ince, Hueseyin ;
Abizaid, Alexandre ;
Toelg, Ralph ;
Lemos, Pedro Alves ;
von Birgelen, Clemens ;
Christiansen, Evald Hoj ;
Wijns, William ;
Neumann, Franz-Josef ;
Kaiser, Christoph ;
Eeckhout, Eric ;
Teik Lim, Soo ;
Escaned, Javier ;
Garcia-Garcia, Hector M. ;
Waksman, Ron .
LANCET, 2016, 387 (10013) :31-39
[8]   Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial [J].
Haude, Michael ;
Erbel, Raimund ;
Erne, Paul ;
Verheye, Stefan ;
Degen, Hubertus ;
Boese, Dirk ;
Vermeersch, Paul ;
Wijnbergen, Inge ;
Weissman, Neil ;
Prati, Francesco ;
Waksman, Ron ;
Koolen, Jacques .
LANCET, 2013, 381 (9869) :836-844
[9]   Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? [J].
Heublein, B ;
Rohde, R ;
Kaese, V ;
Niemeyer, M ;
Hartung, W ;
Haverich, A .
HEART, 2003, 89 (06) :651-656
[10]   Bioresorbable scaffolds: rationale, current status, challenges, and future [J].
Iqbal, Javaid ;
Onuma, Yoshinobu ;
Ormiston, John ;
Abizaid, Alexandre ;
Waksman, Ron ;
Serruys, Patrick .
EUROPEAN HEART JOURNAL, 2014, 35 (12) :765-+